We conducted a systematic review and meta-analysis of studies comparing noninvasive Hb measurements with invasive central laboratory measurements in adult and pediatric patients in critical care settings (operating rooms, intensive care, and emergency departments), as well as in healthy subjects in volunteer settings. The principal measures were the accuracy (mean difference), precision (standard deviation [SD] of mean difference), and 95% LOA of noninvasive Hb measurements compared to invasive central laboratory measurements.
Rationale
Accurate perioperative measurement of hemoglobin (Hb) concentration is of major importance because it can impact decision making related to blood transfusion, which is a major public health issue. 1 Standard Hb measurements are invasive, time-consuming, and painful for patients because they require direct blood sampling. New technologies, however, enable Hb to be measured noninvasively and continuously from a finger probe, and devices based on these technologies are increasingly used in clinical care. 2 Currently, 2 systems are available for the measurement of Hb: multiwavelength co-oximetry (Radical-7™ and Pronto-7™; Masimo Corp., Irvine, CA) and occlusion spectroscopy (NBM-200™, OrSense, Nes Ziona, Israel). The accuracy and precision of these devices have been assessed against central laboratory Hb measurements in clinical settings ranging from critical patients in operating rooms, critical care units, and emergency departments to healthy volunteers in blood donation settings. [3] [4] [5] [6] [7] [8] [9] [10] However, the results of these studies, which are commonly presented with mean difference and 95% limits of agreement (LOA) using Bland-Altman analysis, have been controversial and inconsistent. 11, 12 1. Published studies comparing Hb measured using commercially available noninvasive Hb monitoring systems to that measured by central laboratory Hb measurements in adult and child populations excluding neonates. 2. Studies presenting mean difference or SD of the mean difference (or 95% LOA) between noninvasive Hb monitoring systems and central laboratory Hb measurements.
Information Sources and Search
We conducted a comprehensive search of the medical literature assessing the accuracy of noninvasive Hb monitoring against central laboratory Hb measurements via PubMed, Web of Science, and the Cochrane Library. To establish the search strategy, we first identified the main key (SpHb, oximeter, cooximeter, co-oximetry, spectrophotometric, spectrophotometry, occlusion spectroscopy, rad-57, rad-87, radical-7, Masimo, NBM-200, OrSense, measurement, monitor, determination, continuous, beat-to-beat, real-time, Hb, and noninvasive). We then performed the literature search and applied the search strategy in each of the selected databases with no language restrictions for studies published from 2005 to August 2013 (Masimo Corp. released the commercial version of SpHb in 2005 and OrSense in 2009). The full electronic PubMed search strategy is presented in Appendix 2, Supplemental Digital Content 2, http://links.lww.com/AA/A906. In addition to the database search, we contacted the manufacturers of clinically available monitors, Masimo Corp. and OrSense, for other studies and we hand-searched references in the studies included in the full-text retrieval for studies that had not initially been identified.
Study Selection
Two investigators (SHK and ML) initially screened potentially eligible studies first by title and abstract, eliminating obviously unrelated work. The remaining studies were then retrieved in full text. They assessed eligibility according to inclusion criteria. If the eligibility of the study remained unclear, a third investigator (MC) made the final decision.
Data Collection Process
SHK and ML performed data extraction independently. A specifically designed data extraction sheet was used to perform data extraction from the individual studies. All data were then transferred separately to a standard Excel spreadsheet. SHK and ML reviewed each other's extractions for inconsistencies and if needed returned to the original work to validate the correct data. The minimum published data required to perform metaanalysis were mean difference and SD. We extracted mean difference and SD of mean differences between noninvasive and the central laboratory Hb measurements from a single study. If a study presented only mean difference and 95% LOA, SD was calculated as (upper LOA − mean difference)/1.96. If a Bland-Altman plot was presented but if mean difference and SD were not reported or if only the mean difference without SD or 95% LOA were reported, we contacted the authors of the study to obtain mean difference and SD. If we could not receive data from authors, SD was calculated when 95% confidence interval (CI) of mean difference was reported as follows:
where n = number of paired measurement, SE = standard error. We standardized mean difference in the current metaanalysis to mean noninvasive measurement minus invasive Hb measurement and transformed source data as needed for reporting in this form.
We also extracted demographic data (age, gender distribution, height, weight, or body mass index) and other study characteristics: country where the study was performed, source of funding (industry versus nonindustry), study setting (operating room, intensive care unit, emergency department, blood donation, outpatient clinic or inpatient ward, or study volunteers), name and software version of noninvasive Hb monitoring devices and sensor, name of central laboratory Hb analyzer, sampling site of blood, numbers of patients enrolled and included in the analysis, and total number of paired measurements.
Risk of Bias in Individual Studies
Because there are no specific guidelines for the quality assessment of individual studies in a meta-analysis for method comparison studies, we modified existing guidelines to create an appropriate quality assessment tool. First, we implemented items suggested by the Guidelines for Reporting Reliability and Agreement Studies 14 and the main quality criteria for method comparison studies previously suggested. 11 These were incorporated in the Quality Assessment of Diagnostic Accuracy Studies guidelines (QUADAS-2). 15 We also modified signaling questions and 4 domains for the assessment of risk of bias (patient selection, index test, reference standard, as well as flow and timing) and 3 domains for the assessment of concerns related to applicability (patient selection, index test, and reference standard) from QUADAS-2 guidelines to fit our needs. This process is detailed in Appendix 3, Supplemental Digital Content 3, http://links.lww. com/AA/A907. Using the modified QUADAS-2 form, 2 reviewers (SHK, ML) performed independent quality assessments on each study included in the meta-analysis. Risk for each of the bias domains and each of the applicability domains is classified as low, high, or unclear.
Disagreement between reviewers was resolved by discussion with a third investigator (MC).
Summary Measures
Principal summary measures of the current meta-analysis were mean difference (defined as noninvasive−invasive measurement), SD, and 95% LOA (calculated by mean difference ±1.96 SD of mean differences).
Synthesis of Results
We used random-effects models to summarize overall mean difference and SD as previously reported. 16 to describe heterogeneity of mean differences and SDs across studies. The I 2 describes the percentage of variation across studies that is due to heterogeneity rather than chance in which values of 25%, 50%, and 75% are considered low, moderate, and high, respectively. 18 If there were substantial heterogeneity (I 2 > 50%), we performed sensitivity analysis and meta-regression according to plausible clinical scenarios. Forest plots are presented with individual and random-effects pooled estimates of mean difference and 95% LOA to visualize the data.
Risk of Bias Across Studies
To assess for publication bias, we created funnel plots for mean difference of Hb against standard error for each study. These funnel plots were assessed visually for symmetry. In the absence of bias, these plots would resemble a symmetrical inverted funnel. To formally test for asymmetry, we applied Egger regression tests on secondary funnel plots using a significance level of 0.1 because of the small sample size. 19 
Additional Analysis

Sensitivity Analysis and Subgroup Analysis
We conducted sensitivity and subgroup analyses to explore the causes of heterogeneity. Sensitivity analysis was performed by removing studies in which SD was calculated from SE and on the studies classified as low risk both in the risk of bias domains and applicability concerns domains. We performed subgroup analysis for studies with multiple measurements per subject versus single measurement per subject. Other subgroup analyses included funding source (department versus industry), country of study, type of device, sampling site for the central laboratory Hb measurement, study setting (operating room, intensive care unit, emergency department, blood donation, outpatient clinic or inpatient ward, and study volunteers), and devices (Radical-7, Pronto-7, and NBM-200).
Meta-Regression
We conducted a meta-regression analysis on publication year, country, setting, funding, sample size, device, reference, sampling site, and total number of paired measurement.
All the calculations and tests were conducted using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA) and R. 20 I 2 of mean difference and SD of mean difference were calculated using the following equation:
where Q is test statistic Q used by DerSimonian and Laird, 17 and df is the degrees of freedom. We were able to calculate I 2 for both mean difference and SD because the calculation of I 2 only requires the point estimates from individual studies (see Study Limitations). Data are presented as mean ± SD or mean difference ± SDs (95% LOA).
RESULTS
Study Selection
Four hundred sixty-three articles were retrieved from the database searches and manufacturers after removing duplicates. Two investigators excluded 416 studies by title and abstract screening. The remaining 47 studies were retrieved as full-text articles and were assessed for eligibility. 3 were included in the metaanalysis (Fig. 1) .
Study Characteristics
A total of 4425 subjects were included in this meta-analysis. Characteristics of individual studies are presented in Table 1 . Median sample size of the studies was 44 and ranged from 10 to 569. Across the 25 studies that reported age or gender, the mean age was 45 years and 48% were men. Of the 32 studies included in the meta-analysis, 17 studies [3] [4] [5] [6] 9, 21, [27] [28] [29] 34, 38, [42] [43] [44] 47, 48, 50 were conducted in the perioperative and critical care settings (12 studies performed in the operating room, 3, 4, 9, 21, [27] [28] [29] 34, 38, 43, 44, 48 4 studies in the intensive care unit, 5,6,42,47 and 1 study in both the operating room and the intensive care unit). 50 Four studies were conducted in the emergency department, 22 5 2 studies assessed both Pronto-7 and NBM-200, 32 1 study assessed both Pronto-7 and NBM-200MP, 40 and finally 1 study assessed the RAD-57. 46 
Risk of Bias Within Studies
Results of quality assessment using the modified QUADAS-2 are presented in Appendix 5, Supplemental Digital Content 5, http://links.lww.com/AA/A909. The risk of bias was assessed as low in 16 studies for patient selection, in 28 studies for index test, in 29 studies for reference standard domain, and in 14 studies for the flow and timing domains. Concerns regarding 3 QUADAS-2 applicability domains were assessed as low risk in 32 studies for patient selection, in 28 studies for index test, and in 29 studies for reference standard domain. Interestingly, only 6 studies were rated as low risk both in risk of bias and applicability concerns according to our quality assessment tool incorporating recent recommendation and standards. 5, 9, 28, 36, 42, 44 
Synthesis of Results
Overall Meta-Analysis Individual, subtotal, and pooled random-effects mean difference and 95% LOA for the 32 included articles are shown in Figure 2 . SD was calculated using the formula for conversion from 95% CI in 2 studies. 47, 50 The pooled mean difference and SD were 0.10 ± 1.37 g/dL (−2.59 to 2.80 g/dL). We found high level of heterogeneity for both mean difference (I 2 = 95.9%) and SD (I 2 = 95.0%).
Risk of Bias Across Studies
Funnel plot constructed for mean difference for Hb against SE appeared symmetrical, and Egger regression test for asymmetry showed nonsignificant P values (P = 0.861; Fig. 3 ). ANesthesiA & ANAlgesiA
Continuous Noninvasive Hemoglobin Monitoring
Additional Analysis
Sensitivity Analysis and Subgroup Analysis
Pooled mean difference and SD in the sensitivity analysis after removing data from studies in which SDs were calculated from SE was not different from the overall meta-analysis. Sensitivity analysis conducted on the 6 studies classified as low risk both in the risk of bias domains and applicability concerns domains did not reduce heterogeneity across studies. The pooled mean difference and SD of these studies was 0.08 ± 1. 46 
Subgroup Analysis by Device
Pooled mean difference and SD were similar among 3 devices. Heterogeneity for mean difference across studies was still substantial ( Table 2) .
Meta-Regression
There was significant residual heterogeneity after metaregression analysis according to plausible explanatory scenarios. The publication year was associated with mean difference with P < 0.05 with meta-regression test, but there was still heterogeneity after accounting for the effect of this factor (Appendix 6, Supplemental Digital Content 6, http:// links.lww.com/AA/A910).
DISCUSSION
Summary of Evidence
This meta-analysis of 32 studies including 4425 subjects and assessing accuracy and precision of noninvasive Hb measurement compared to central laboratory Hb measurements showed that the overall random-effects pooled mean difference and SD was 0.10 ± 1.37 g/dL (−2.59 to 2.80 g/dL).
We found significant between-study heterogeneity for both mean differences and SD. In the perioperative and critical care setting, these were 0.39 ± 1.32 g/dL (−2.21 to 2.98 g/dL) and −0.51 ± 1.59 g/dL (−3.63 to 2.62 g/dL), respectively. Heterogeneity was still high even after sensitivity analysis including only studies in critical care settings. Among 32 studies meeting inclusion criteria in the current meta-analysis, only 6 were rated as low risk in both risk of bias and applicability concerns based on our quality assessment tool, which incorporated recent recommendations and standards for method comparison studies. The goal of this meta-analysis was to assess the agreement between noninvasive Hb measurements and central laboratory Hb measurements. This topic has raised significant interest in the anesthesiology, critical care, and emergency settings during the past 5 years because of the impact such technologies may have on patient management and blood transfusion practices. 12 Several small, single-center studies have been conducted on the topic, and our goal was to inform clinicians using this technology at the bedside about the accuracy and the precision of these devices. From our results, health care providers should still be cautious when making clinical decision about blood transfusion based on these technologies. For example, if Hb measured using a central laboratory analyzer was 10 g/dL, Hb measured using one of the noninvasive Hb measurement devices tested in this meta-analysis could range anywhere between 7.4 and 12.8 g/dL. In the operating room setting (where 13 of the 32 studies included in our meta-analysis were conducted), if Hb measured using a central laboratory analyzer was 10 g/dL, Hb measured using one of the noninvasive Hb measurement device could range anywhere between 7.8 and 13.0 g/dL. Practically speaking, based on the overall accuracy and precision of the current meta-analysis, we recommend measuring Hb invasively if the noninvasive Hb level is <8.69 g/dL. This implies that at least 2.5% of the laboratory Hb level will be <6.0 g/dL, which is the transfusion trigger in the current guidelines. Inversely, one can expect that 97.5% of the laboratory Hb level will lie above 10.0 g/dL when the noninvasive Hb level is higher than 12.69 g/dL. The decision to measure invasive Hb between these levels depends on the clinical situation.
Considering the importance of blood transfusion in the perioperative period and the commonly accepted transfusion triggers, the lack of accuracy and precision in the current generation of these devices may negatively affect clinicians' decisions about their patients. It should be noted, however, that other point-of-care Hb measurement devices have similarly large error ranges, but this has not prevented their routine use in clinical care. 23 For example, the HemoCue portable hemoglobinometer (HemoCue; HemoCue AB, Ängelholm, Sweden) when tested against central laboratory standards has been shown to have a mean difference and SD of −0.1 ± 1.6 g/dL, and other studies have shown similarly wide LOA. 8, 10, 61, 62 In a direct head-to-head clinical trial, the LOA of the HemoCue device were found to be narrower than the Radical-7, but a portion of patients had >1.0 g/dL and even a 1.5 g/dL error compared to central laboratory testing for both devices. 21 This underlines the challenges our community has faced with in the past to evaluate new monitoring systems and define what makes a new monitor acceptable or not. As recently discussed by Riou, 11 method comparison studies lack clear standards. This is reflected by the overall low quality of the studies included in our meta-analysis. We believe that clear standards for conducting method comparison studies would help our community to better evaluate new monitors while at the same time promoting innovation.
Moreover, clinical decisions are often based on serial Hb measurements, and the ultimate goal of these technologies would be to both decrease unnecessary transfusions and simultaneously prompt earlier intervention when truly needed. 63 Because of this, some authors have suggested alternative methods for the evaluation of these noninvasive and continuous Hb measurement systems (error grid for instance). 12 In our review, we focused only on the agreement between these new technologies and invasive central laboratory measurements because recommendations for blood transfusion are principally based on specific cutoff points. 1 Thus, it is of major importance to be able to correctly classify patients as being above or below these thresholds, and this starts first with the evaluation of the agreement between a new technology and a "gold standard." 64, 65 One of the findings from this meta-analysis is that 6 of the 32 studies included were rated as low risk both in risk of bias and applicability concerns according to the criteria we used in our revised QUADAS-2 assessment sheet (Appendix 5, Supplemental Digital Content 5, http://links.lww.com/ AA/A909). This confirms what had already been suggested by other authors on the overall quality of conduct and report of method comparison studies. 11 In the revised quality assessment sheet used in our study, we integrated recommendations from recent guidelines 14 and opinion leaders, including suggestions from a recently published editorial on the topic 11 describing the main quality criteria for the report of method comparison studies. Only 6 studies 5, 9, 28, 36, 42, 44 (19 %) included in this meta-analysis met all the criteria from our revised QUADAS-2. The inconsistency and the relatively poor quality of studies conducted on the topic suggest that guidelines and recommendations regarding how these studies should be conducted and reported would be beneficial to our community. Recommendations similar to those published for randomized control trials (Consolidated Standards of Reporting Trials) 66 or diagnostic accuracy studies (Standards for Reporting of Diagnostic Accuracy) 67 would be very useful. 11 We found significant heterogeneity among studies included in our meta-analysis but were not able to identify causes even after performing a series of subgroup analyses, sensitivity analyses, and meta-regressions. Multiple factors may be responsible, and each factor may contribute to a small proportion of the total. Interestingly, several previously published meta-analyses of method comparison studies (arterial blood pressure measurements 68 and temperature measurements) 69, 70 found similar heterogeneity and were similarly not able to identify causes, despite extensive statistical analysis. In the present meta-analysis, use of different devices, different populations, different central laboratory analyzers, subtle differences in arterial blood versus venous blood, as well as the quality of the studies included in the meta-analysis may have contributed to the overall variation. The precision of industry-supported studies was 0.24 ± 1.02.
Study Limitations
First, our meta-analysis does not assess the potential clinical utility of these noninvasive Hb measurement devices. While we understand that the potential impact of a new monitoring technology on clinical decision making, patient outcome, and/ or patient safety encompasses far more than the simple assessment of accuracy and precision of these systems, we believe that Hb is such an important variable for patient management that strong recommendations about the way the accuracy and precision of these systems should be evaluated and reported should be published before any outcome study is conducted. In the future, we suggest that studies assessing the effectiveness of this technology using pragmatic approaches and comparative effectiveness research methodologies will help better understand the role of these devices in our daily practice.
Second, we studied a mixture of different devices for noninvasive and invasive Hb measurements in this metaanalysis. We included studies focusing on the evaluation of 3 different technologies (Radical-7, Pronto-7, NBM-200, and NBM-200MP), and we included studies evaluating the accuracy and precision of these devices against different central laboratory analyzers, using different blood origins (arterial and venous). Unfortunately, this is the way these studies have
ANesthesiA & ANAlgesiA
Continuous Noninvasive Hemoglobin Monitoring been conducted, which is part of the rationale for clear guidelines and standardization of method comparison studies.
Third, we did not present 95% CIs of mean difference and SD. We could not calculate the 95% CIs of the pooled SD because we did not have information regarding the accuracy of SD from individual studies. We have not found any publications that provide statistical methods to quantify the uncertainty of SD in meta-analysis. Consequently, we presented the results of the current meta-analysis with mean difference and 95% LOA as proposed previously. 16, 69, 70 In addition, regarding the SD of the mean difference between 2 methods within a single study, some studies performed only 1 measurement per subject, whereas other studies performed multiple measurements per subject. If the current meta-analysis had complete data from all studies available, we would have had a multilevel (hierarchical) model and could have calculated the accuracy of SD. Without complete data from all the studies, given the information reported in at least some of those studies that had multiple measurements in each subject, we could not perform a multilevel hierarchical model. We performed subgroup analysis to account for the issue of multiple measurements. As demonstrated in subgroup analysis, the results are similar between studies with single and multiple measurements. Therefore, we assume that this issue does not confound the result substantially.
Finally, our research strategy was limited to PubMed, Web of Science, Cochrane Library, and to articles provided by manufacturers, and only included studies published in peer-reviewed journals. We limited the search to peerreviewed publications to avoid low-quality manuscripts and because the impact of the inclusion of "gray literature" in meta-analyses is still unclear, especially for meta-analysis of method comparison studies. However, it is possible that different search strategies could result in different conclusions.
CONCLUSIONS
Our meta-analysis showed that the overall random-effects pooled mean difference and SD of noninvasive Hb measurements compared to invasive central laboratory measurements was 0.10 ± 1.37 g/dL (−2.59 to 2.80 g/dL). Although the mean difference between noninvasive Hb and central laboratory measurements were small, the wide LOA mean clinicians should be cautious when making clinical decisions based on these devices. E
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